Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Fountain, CR, and Havrilesky, LJ. "Promoting Same-Day Discharge for Gynecologic Oncology Patients in Minimally Invasive Hysterectomy." Journal of minimally invasive gynecology 24, no. 6 (September 2017): 932-939.

Full Text

Havrilesky, LJ. "The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer." Gynecologic oncology 146, no. 3 (September 2017): 441-442.

Full Text

Dilley, SE, Havrilesky, LJ, Bakkum-Gamez, J, Cohn, DE, Michael Straughn, J, Caughey, AB, and Rodriguez, MI. "Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention." Gynecologic oncology 146, no. 2 (August 2017): 373-379.

Full Text

Havrilesky, LJ, Moss, HA, Chino, J, Myers, ER, and Kauff, ND. "Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers." Gynecologic oncology 145, no. 3 (June 2017): 549-554.

Full Text

Wenzel, L, Mukamel, D, Osann, K, Havrilesky, L, Sparks, L, Lipscomb, J, Wright, AA, Walker, J, Alvarez, R, Van Le, L, Robison, K, Bristow, R, Morgan, R, Rimel, BJ, Ladd, H, Hsieh, S, Wahi, A, and Cohn, D. "Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients." Contemporary clinical trials 57 (June 2017): 29-36.

Full Text

Moss, H, Myers, E, Berchuck, A, and Havrilesky, LJ. "Cost-effectiveness of ovarian cancer screening: An analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) from a US health system perspective." May 20, 2017.

Full Text

Gaillard, S, Dumbauld, C, Bilewski, A, Ehrisman, JA, Secord, AA, Havrilesky, LJ, Berchuck, A, Weinhold, K, Chan, C, and Yi, J. "Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8(+) T cells in ovarian cancer." May 20, 2017.

Full Text

Foote, J, Havrilesky, LJ, Jewell, EL, Gamble, C, Ehrisman, J, Broadwater, G, Coleman, RL, Cohn, DE, and Secord, AA. "Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO's net health benefits (NHB) inform our decisions?." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 6, 2017.: AMER SOC CLINICAL ONCOLOGY, May 20, 2017.

Full Text

Wenzel, LB, Mukamel, DB, Osann, K, Sparks, L, Havrilesky, LJ, Wright, AA, Walker, JL, Robison, K, Alvarez, RD, Van Le, L, Wakabayashi, MT, Randall, LM, Wahi, A, Hsieh, S, Lipscomb, J, and Cohn, DE. "Shared decision-making in ovarian cancer." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 6, 2017.: AMER SOC CLINICAL ONCOLOGY, May 20, 2017.

Full Text

Hong, JC, Foote, J, Broadwater, G, Gaillard, S, Havrilesky, LJ, and Chino, JP. "Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 27, no. 4 (May 2017): 720-729.

Full Text

Pages